整理 | GLP1减重宝典内容团队 近日，合肥海关所属庐州海关关员在对进境邮件进行CT机检查验时，发现图像异常，经开箱查验，发现大量用透明塑料袋封装的减肥 药品。该批药品色泽鲜艳、大小不一，无生产日期、无质量合格证明、无生产厂家。经现场快速检测，该批药品中含有违禁成分甲基 安非他明，共计600粒。 JOIN GLP-1 CLUB 甲基安非他明是一种强效的中枢神经系统兴奋剂，是冰毒的有效成分，被列为第一类精神药品，具有成瘾性。根据《中华人民共和国 药品管理法》规定，进口、出口麻醉药品和国家规定范围内的精神药品，应当持有国务院药品监督管理部门颁发的进口准许证、出口 准许证。目前，海关已依法对该批减肥药品予以暂扣。 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 加入专家库与我们深度讨论 「GLP-1俱乐部」覆盖数百位专业人士，构建了围绕GLP-1产业链上下游、覆盖多个板块的专家库，成为了业内顶尖专业人士 ...

Core Viewpoint - Novo Nordisk's weight loss drug Wegovy has received accelerated approval from the FDA for the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH), solidifying the company's position in the metabolic disease sector [6][8]. Summary by Sections FDA Approval and Market Position - Wegovy is the first GLP-1 class drug approved for MASH, a serious liver disease affecting approximately 5% of U.S. adults according to the American Liver Foundation [6]. - Novo Nordisk is now one of only two FDA-approved therapies for MASH, with the other being Madrigal Pharmaceuticals' Rezdiffra, approved in 2024 [6]. Clinical Study Results - In a study, 62.9% of patients treated with 2.4 mg semaglutide experienced relief from steatohepatitis without worsening fibrosis, compared to 34.3% in the placebo group, showing a significant difference of 28.7% (P<0.001) [7]. - For the second primary endpoint, 36.8% of the semaglutide group showed improvement in fibrosis without worsening fatty liver, versus 22.4% in the placebo group, with a difference of 14.4% (P<0.001) [7]. - The study's first part highlights the potential of semaglutide to delay the progression of cirrhosis and end-stage liver disease [7]. Treatment Availability and Future Plans - Wegovy is now available in the U.S. for adults with MASH and moderate to severe fibrosis, requiring a balanced diet and exercise [8]. - Novo Nordisk is working with insurers to expand coverage but has not disclosed specific pricing [8]. - The company has applied for approval in Europe and Japan based on the study's first part results, with complete data from the second part expected in 2029 [8]. Competitive Landscape - Eli Lilly is also developing treatments for MASH, with its active ingredient tirzepatide showing that up to 74% of patients achieved resolution of MASH without worsening fibrosis in a mid-stage study [8].